Pharmaceutical Bloggers Busy This Week with Discussions of FDARevitalization Act and Off-label Marketing
NEWTOWN, Pa., May 11, 2007 – This week, the PharmaBlogs: Week in Review e-newsletter addresses the passing of the FDA Revitalization Act, key components that have been stricken from the bill, and the measure allowing FDA to fine companies $150,000 per violation for running false or misleading ads. Also called into light are the lawsuit filed by two Johnson & Johnson employees and the $634 million Purdue Pharma settlement, both for off-label marketing practices. Somewhat lighter topics among the industry’s blogs this week include patient gift-giving guidelines and questionable physician ties to the industry. Christiane Truelove, editor of Med Ad News and R&D Directions, summarizes the thoughts of popular industry bloggers on these topics.
About PharmaBlogs: Week in Review
Designed as a time-effective approach to keeping current on the industry’s blog discussions, PharmaBlogs: Week in Review is the first online newsletter focused on recapping pharmaceutical blogs. The e-newsletter is published by industry information provider Engel Publishing Partners and sent to your e-mail inbox each Friday.
About Engel Publishing Partners
For 25 years, Engel Publishing Partners has been the source that pharmaceutical executives turn to for the information they need to create competitive business strategies. Engel Publishing Partners carries a full product line offering industry-leading publications Med Ad News and R&D Directions, informative newsletters, and data-rich interactive products. Through these channels, Engel disseminates original and un-biased content that provides insight into industry trends and events, as well as extensive analysis of companies, products, and pipelines.
Posted: May 2007